

Labbex Förvaltnings AB Increases its Ownership in AroCell

Labbex Förvaltnings AB, which currently owns 11.58 percent of the shares in AroCell AB, is increasing its ownership by 6.77 percentage points and, after the acquisition, will own 18.35 percent of the shares and votes in AroCell AB.

The acquisition of the shares was executed through a block trade, and Labbex Förvaltnings AB acquired 15,600,000 shares from Agartha AB. This strategic investment further strengthens Labbex Förvaltnings AB's ownership in AroCell and demonstrates their continued strong belief in AroCell's future. Max Pihlqvist, owner of Labbex Förvaltnings AB, also privately owns 2,134,154 shares, corresponding to 0.93 percent of the shares in the company.

"I am pleased with the opportunity to increase Labbex Förvaltnings' ownership in AroCell. AroCell is in a robust growth phase and has several diagnostic products on the market that are currently in routine clinical use, benefitting both patients and healthcare providers. At the same time, the company has a strong financial position that enables exciting development opportunities moving forward. I view the future with great confidence and am proud to be a part of the company," says Max Pihlqvist, owner of Labbex Förvaltnings AB and Chairman of the Board of AroCell AB.

"Labbex has extensive experience in managing companies within the diagnostics industry, while Agartha prefers to focus on its core business within the real estate industry. I wish Labbex Förvaltnings AB and AroCell continued success in the future," says Greg Dingizian, Chairman of Agartha AB.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Press Release
02 January 2025 10:10:00 CET



Attachments

[Labbex Förvaltnings AB Increases its Ownership in AroCell](#)